GILD

These 2 Biotech Stocks Are Set To Split The $15 Billion Hepatitis C Market

View gallery.A recent report by Morgan Stanley predicts a greater than 40 percent growth in the Hepatitis C (HCV) market in 2015. Projections indicate that the HCV market could be worth $15 billion in upcoming years, with two-thirds of treatment occurring in the United States.
HCV Forerunners Gilead And AbbVie
Morgan Stanley projects that Gilead Sciences, Inc.’s (NASDAQ: GILD) Harvoni and Sovaldi […]

Biotech Stock Roundup: Geron Soars on $935M J&J Deal, Gilead's …

Geron Corporation (GERN – Analyst Report) was in the spotlight last week with the company striking a collaboration deal with Johnson & Johnson for its sole pipeline candidate, imetelstat. Meanwhile, companies like Gilead (GILD – Analyst Report) and Regeneron (REGN – Analyst Report) remained in the news thanks to regulatory updates.Recap of the Week’s Most Important Stories1. Geron, which had […]

SPY, DIA Make Another New All-time Closing High, QQQ 14-year High as SOX and Financials Rise…

All nine sectors moved higher on Tuesday…XLV, XLB and XLI were the strongest sectors while XLE was the weakest.Breadth strengthened as advancers led decliners…1.53 to 1 on the NYSE and 1.52 to 1 on the NASDAQTuesday – strengthened, advancers ledMonday – weakened, decliners ledFriday – strengthened, advancers led NYSEThursday – weakened, decliners ledWednesday – strengthened, advancers ledSPY up 1.18 at […]

Buy These Five Beaten-Down Biotech Stocks, Nomura Says – Stocks …

By Ben LevisohnYes, say the folks at Nomura, who recommend buying Celgene (CELG), Receptos(RCPT), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), and Alexion Pharmaceuticals (ALXN), in that order. Analyst M. Ian Somaiya and team explain why:

October has historically been a weak month for biotech, with the Nasdaq Biotechnology Index underperforming the S&P 500 in 14 out the last 20 years. We believe […]

Stock Market News for July 31, 2014 – Zacks Investment Research

Second quarter GDP gained momentum, fuelled by improved consumer spending. Real personal consumption expenditure accelerated in spring by 2.5% following a 1.2% increase in the first quarter.In addition to this, growth was boosted by a pickup in construction spending, increased business spending on equipment, a bigger buildup in inventories and slightly higher government spending.This rise in second quarter GDP was […]

Gilead Announces Results from Phase 2 Study Showing Reduction in Atrial Fibrillation Burden with the Investigational Combination of Ranolazine and Low-Dose Dronedarone

[Business Wire] – Gilead Sciences, Inc. today announced results from HARMONY, a randomized, double-blind, placebo-controlled Phase 2 study evaluating the effect of ranolazine and low-dose dronedarone, each given alone and in combination, on atrial fibril moreView todays social media effects on GILDView the latest stocks trending across Twitter. Click to view dashboardSee who Gilead is hiring next, click here to […]

Gilead Announces Phase 1 Data for Investigational Therapy, GS-6615, in Patients with Long QT-3 Syndrome

[Business Wire] – Gilead Sciences, Inc. today announced results from a Phase 1 clinical trial of GS-6615, an investigational, selective late sodium current inhibitor, showing a shortening of the QTc interval in patients with long QT-3 syndrome. moreView todays social media effects on GILDView the latest stocks trending across Twitter. Click to view dashboardSee who Gilead is hiring next, click […]